Actemra

Understanding Actemra® 

Actemra® (tocilizumab) is a monoclonal antibody that helps regulate the immune system by blocking interleukin-6 (IL-6) receptors, a key driver of inflammation in autoimmune diseases. It is used to treat various types of arthritis and immune-related conditions when other treatments, such as TNF inhibitors, have not been effective.

How Actemra® Works:

  • Targets and blocks IL-6 receptors, reducing the effects of IL-6, a protein that causes inflammation.
  • Helps protect healthy cells from immune system attacks, minimizing inflammation and joint damage.
  • Reduces joint pain, swelling, and stiffness in arthritis patients.
  • Lowers the risk of vascular complications in Giant Cell Arteritis (GCA).

FDA Approval:

  • 2010 – Approved for Rheumatoid Arthritis and other autoimmune conditions.

For more information, please visit the Actemra® patient website. Speak with your healthcare provider to determine if Actemra® is the right treatment option for you.

Referral Form

What it Treats

Manufacturer

Genentech

Class

Biologics (Interleukin-6 inhibitor)

Prescribed by

How Administered

IV Infusion or Subcutaneous Injection.

Frequency

Every four weeks for RA, weekly for GCA, and every two, three, or four weeks for JIA.

Length of infusion

About 60 minutes

Other Treatments

Get in touch

Phone

732 931 4633
732 413 2421 (FAX)

Address

Monmouth County
Long Branch, NJ 07740